Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02497716 · ClinicalTrials.gov registry record · Phase 1
Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT02497716 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 47 participants.
The verdict
NCT02497716, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02497716
The ClinicalTrials.gov registry entry for NCT02497716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivaroxaban (Xarelto, BAY59-7939 is the first listed.
NCT02497716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02497716 about?
NCT02497716 is a clinical study titled "Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children". To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability
What is the current status of trial NCT02497716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2015-11-04. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT02497716?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939 (DRUG).
Who is sponsoring clinical trial NCT02497716?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.